Insured Purchase
This report comes with a service guarantee — we stand behind the quality and accuracy of our research.
Digital Therapeutics (DTx) Market: Regulatory Pathways, Reimbursement Models, and Therapeutic Area Growth (2025?2030)
-
Published Date: September, 2024
-
Report ID: Trend06112556
-
Format: Electronic (PDF)
-
Number of Pages: 47
Report Overview
Digital Therapeutics are finally moving from the wellness app niche into the core of evidence-based medicine. This report analyzes the 2025?2030 forecast period, where prescription digital therapeutics are becoming a standard of care for type 2 diabetes and insomnia. The primary driver explored is the maturation of reimbursement pathways; as health insurers move toward value-based care, they are increasingly covering DTx products that demonstrate real-world clinical outcomes. We analyze the Drug-plus-Digital model, where pharma companies bundle pills with digital companions to improve patient adherence. The narrative also details the rise of VR-based therapeutics for pain management. By 2030, the DTx market will be defined by its integration into Electronic Health Records, allowing doctors to prescribe software with the same ease as a chemical compound, creating a new category of data-driven medicine.
Table of Contents
1. Software-as-a-Drug; 2. Clinical Validation; 3. Reimbursement Breakthrough; 4. Mental Health/Obesity; 5. Pharma Partnerships; 6. Outlook.